UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis
USA - NYSE:UTI - US9139151040 - Common Stock
27.66 USD
+0.09 (+0.33%)
27.66 USD
0 (0%)
Overall UTI gets a fundamental rating of 6 out of 10. We evaluated UTI against 74 industry peers in the Diversified Consumer Services industry. While UTI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. UTI is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make UTI suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year UTI was profitable.
In the past year UTI had a positive cash flow from operations.
UTI had positive earnings in each of the past 5 years.
In the past 5 years UTI always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of UTI (8.52%) is better than 78.38% of its industry peers.
Looking at the Return On Equity, with a value of 20.57%, UTI belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
The Return On Invested Capital of UTI (10.86%) is better than 83.78% of its industry peers.
UTI had an Average Return On Invested Capital over the past 3 years of 5.11%. This is below the industry average of 9.88%.
The 3 year average ROIC (5.11%) for UTI is below the current ROIC(10.86%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.52% | ||
| ROE | 20.57% | ||
| ROIC | 10.86% |
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
1.3 Margins
UTI's Profit Margin of 7.79% is fine compared to the rest of the industry. UTI outperforms 67.57% of its industry peers.
UTI's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 10.44%, UTI is in the better half of the industry, outperforming 68.92% of the companies in the same industry.
In the last couple of years the Operating Margin of UTI has grown nicely.
UTI has a Gross Margin (49.65%) which is in line with its industry peers.
UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.44% | ||
| PM (TTM) | 7.79% | ||
| GM | 49.65% |
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTI is still creating some value.
The number of shares outstanding for UTI has been increased compared to 1 year ago.
Compared to 5 years ago, UTI has more shares outstanding
The debt/assets ratio for UTI has been reduced compared to a year ago.
2.2 Solvency
UTI has an Altman-Z score of 3.71. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
UTI has a Altman-Z score of 3.71. This is in the better half of the industry: UTI outperforms 78.38% of its industry peers.
UTI has a debt to FCF ratio of 0.99. This is a very positive value and a sign of high solvency as it would only need 0.99 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.99, UTI belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that UTI is not too dependend on debt financing.
UTI has a Debt to Equity ratio (0.23) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 0.99 | ||
| Altman-Z | 3.71 |
ROIC/WACC1.3
WACC8.37%
2.3 Liquidity
A Current Ratio of 1.00 indicates that UTI should not have too much problems paying its short term obligations.
UTI has a Current ratio of 1.00. This is comparable to the rest of the industry: UTI outperforms 41.89% of its industry peers.
UTI has a Quick Ratio of 1.00. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
UTI has a Quick ratio of 1.00. This is comparable to the rest of the industry: UTI outperforms 47.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 128.00% over the past year.
The Earnings Per Share has been growing by 28.35% on average over the past years. This is a very strong growth
UTI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.56%.
UTI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.19% yearly.
EPS 1Y (TTM)128%
EPS 3Y28.35%
EPS 5YN/A
EPS Q2Q%111.11%
Revenue 1Y (TTM)14.56%
Revenue growth 3Y29.79%
Revenue growth 5Y17.19%
Sales Q2Q%15.12%
3.2 Future
The Earnings Per Share is expected to grow by 11.29% on average over the next years. This is quite good.
UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
EPS Next Y45.26%
EPS Next 2Y16.33%
EPS Next 3Y11.29%
EPS Next 5YN/A
Revenue Next Year14.42%
Revenue Next 2Y11.32%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.26, UTI is valued on the expensive side.
UTI's Price/Earnings ratio is a bit cheaper when compared to the industry. UTI is cheaper than 63.51% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. UTI is around the same levels.
A Price/Forward Earnings ratio of 27.62 indicates a quite expensive valuation of UTI.
UTI's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, UTI is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.26 | ||
| Fwd PE | 27.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTI is valued a bit cheaper than 67.57% of the companies in the same industry.
UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 70.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.14 | ||
| EV/EBITDA | 10.13 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y16.33%
EPS Next 3Y11.29%
5. Dividend
5.1 Amount
UTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.66
+0.09 (+0.33%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)
Earnings (Next)
Inst Owners92.66%
Inst Owner Change-1.39%
Ins Owners2.22%
Ins Owner Change-2.45%
Market Cap1.51B
Analysts81.82
Price Target38.18 (38.03%)
Short Float %4.36%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.27%
Min EPS beat(2)69.26%
Max EPS beat(2)73.27%
EPS beat(4)4
Avg EPS beat(4)69.47%
Min EPS beat(4)12.21%
Max EPS beat(4)123.12%
EPS beat(8)7
Avg EPS beat(8)80.23%
EPS beat(12)10
Avg EPS beat(12)129.78%
EPS beat(16)14
Avg EPS beat(16)215.22%
Revenue beat(2)2
Avg Revenue beat(2)2.83%
Min Revenue beat(2)1.15%
Max Revenue beat(2)4.51%
Revenue beat(4)4
Avg Revenue beat(4)2.54%
Min Revenue beat(4)1.15%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.39%
Revenue beat(12)11
Avg Revenue beat(12)2.98%
Revenue beat(16)15
Avg Revenue beat(16)3.43%
PT rev (1m)0%
PT rev (3m)0.26%
EPS NQ rev (1m)-4.63%
EPS NQ rev (3m)-19.84%
EPS NY rev (1m)1.78%
EPS NY rev (3m)2.01%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.26 | ||
| Fwd PE | 27.62 | ||
| P/S | 1.86 | ||
| P/FCF | 20.14 | ||
| P/OCF | 13.97 | ||
| P/B | 4.91 | ||
| P/tB | 5.77 | ||
| EV/EBITDA | 10.13 |
EPS(TTM)1.14
EY4.12%
EPS(NY)1
Fwd EY3.62%
FCF(TTM)1.37
FCFY4.96%
OCF(TTM)1.98
OCFY7.16%
SpS14.88
BVpS5.64
TBVpS4.79
PEG (NY)0.54
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.52% | ||
| ROE | 20.57% | ||
| ROCE | 15.21% | ||
| ROIC | 10.86% | ||
| ROICexc | 13.78% | ||
| ROICexgc | 15.4% | ||
| OM | 10.44% | ||
| PM (TTM) | 7.79% | ||
| GM | 49.65% | ||
| FCFM | 9.23% |
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
ROICexc(3y)7.05%
ROICexc(5y)N/A
ROICexgc(3y)7.97%
ROICexgc(5y)N/A
ROCE(3y)7.15%
ROCE(5y)N/A
ROICexcg growth 3Y41.64%
ROICexcg growth 5YN/A
ROICexc growth 3Y37.09%
ROICexc growth 5YN/A
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
F-Score6
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 0.99 | ||
| Debt/EBITDA | 0.51 | ||
| Cap/Depr | 59.94% | ||
| Cap/Sales | 4.08% | ||
| Interest Coverage | 11.6 | ||
| Cash Conversion | 77.19% | ||
| Profit Quality | 118.43% | ||
| Current Ratio | 1 | ||
| Quick Ratio | 1 | ||
| Altman-Z | 3.71 |
F-Score6
WACC8.37%
ROIC/WACC1.3
Cap/Depr(3y)213.97%
Cap/Depr(5y)231.88%
Cap/Sales(3y)10.54%
Cap/Sales(5y)10.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128%
EPS 3Y28.35%
EPS 5YN/A
EPS Q2Q%111.11%
EPS Next Y45.26%
EPS Next 2Y16.33%
EPS Next 3Y11.29%
EPS Next 5YN/A
Revenue 1Y (TTM)14.56%
Revenue growth 3Y29.79%
Revenue growth 5Y17.19%
Sales Q2Q%15.12%
Revenue Next Year14.42%
Revenue Next 2Y11.32%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
EBIT growth 1Y85.69%
EBIT growth 3Y58.11%
EBIT growth 5YN/A
EBIT Next Year116.51%
EBIT Next 3Y34.92%
EBIT Next 5YN/A
FCF growth 1Y395.38%
FCF growth 3YN/A
FCF growth 5Y32.12%
OCF growth 1Y222.73%
OCF growth 3Y15.89%
OCF growth 5Y31.61%